Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Interpace Biosciences Announces Third Quarter 2020 Financial and Business Results and .
Interpace Biosciences, Inc.January 20, 2021 GMT
Third Quarter Net Revenue of $8.2 Million Up 7% vs Prior Year; Third Quarter Year to Date Net Revenue of $22.8 Million Up 14% vs Prior Year
Estimates Fourth Quarter Net Revenue range of $9.0 million - $10.0 million
Realized Reimbursement on Higher ThyGeNEXT Pricing in January
Closed $5 Million Bridge Loan Agreement with Existing Private Equity Investors and terminated the SVB credit facility
Cash balance as of January 15, 2021 was $6.1 million net of restricted cash
Conference Call and Webcast Thursday January 21, 2021 at 4:30 pm ET
Nexelis acquires the GSK vaccines clinical bioanalytical laboratory located in Marburg – Germany and enters into a 5-year strategic agreement with GSK. Laval, Quebec, and Marburg, Germany, January 20, 2021. Nexelis,a portfolio company of Ampersand Capital Partners, and a leading provider of advanced assay development and laboratory testing services in the infectious, oncologic, and metabolic […]
Share this article
Share this article
LAVAL, QC and MARBURG, Germany, Jan. 20, 2021 /PRNewswire/ - Nexelis, a portfolio company of Ampersand Capital Partners, and a leading provider of advanced assay development and laboratory testing services in the infectious, oncologic, and metabolic diseases fields, has signed an asset purchase agreement with GSK to acquire its GCLP-certified clinical bioanalytical laboratory located in Marburg, Germany.
The Clinical Laboratory Science (CLS) team in Marburg, consisting of approximately 80 scientists and analysts, will be transferred to Nexelis. The CLS team in Marburg will continue to keep a strong relationship with GSK and support the development of future GSK vaccine candidates through a 5-year strategic collaborative agreement.
Los Angeles County Employees preps private equity consultant search
Print
Los Angeles County Employees Retirement Association, Pasadena, Calif., plans to launch an RFP for a private equity consultant sometime before Jan. 21, said Jonathan Grabel, CIO of the $60 billion pension fund.
Incumbent Stepstone Group s contract is set to expire in October. Stepstone will be invited to rebid. A selection is expected as early as September. LACERA has $7.1 billion invested in private equity and a private equity target of 10% with an allocation range of 7% to 13%.
Separately, the board on Dec. 9 approved a growth structure review, the primary planning document for its growth asset class. LACERA has $29.4 billion in the asset class, which includes global equity, private equity and real estate.